Skip to main content

Table 2 Comparison of high risk variables between chronic hepatitis C (CHC) and hepatocellular carcinoma (HCC) patients

From: Chronic hepatitis c genotype-4 infection: role of insulin resistance in hepatocellular carcinoma

Variables CHC
N = 50
N(%)
HCC
N = 50
N(%)
Odds ratio P-value
Age     
>57years 20(40) 30(60) 0.44 (0.20-0.99) 0.04
Male gender 30(60) 31(62) 1.09(0.49-2.43) 0.84
Obese (BMI >25) 22(44) 20(40) 1.18(0.53-2.61) 0.68
LFT     
ALT (>37 IU/L) 46(92) 47(94) 0.73(0.16-3.46) >0.99
AST (>40 IU/L) 37(74) 50(100) 1.35(1.15-1.59) <0.001
T. Bil (> 1 mg/dL) 24(48) 50(100) 2.08(1.56-2.78) <0.001
Albumin (>5.3 g/dL) 0 0   
INR (> 1) 32(64) 50(100) 1.56(1.27-1.92) <0.001
GGT (>50 IU/L) 30(60) 50(100) 1.67 (1.33-2.09) <0.001
Biochemical tests     
Fasting Glucose     
(>110 mg/dL) 48(96) 42(84) 4.57(0.92-22.73) 0.09
Fasting Insulin (>6.IU/mL) 37(74) 42(84) 0.54 (0.20-1.45) 0.22
HbA1c (>7%) 24(48) 35(70) 0.40(0.17-0.90) 0.02
HOMA-IR (>4) 20(40) 26 (52) 1.63 (0.74-3.59) 0.23
Plt (>400 × 109/L) 0 0   -
Cholesterol (>200 mg/dL) 17(34) 20(40) 1.29 (0.57-2.92) 0.63
TG (> 150 mg/dL) 48(96) 47(94) 1.53(0.24-9.59) >0.99
Tumor marker     
Serum AFP (>10 ng/mL) 30(12-57) 255(220-310) 26.00(6.68-101.20) <0.001
HCV RNA (viral load) N(%)     
Moderate (100-1000 × 103) n = 56 21(42) 35(70) - <0.001
Stage of Fibrosis     
III-V (n = 83) 34(68) 49(98) 23.06 (2.92-82.21) <0.001
  1. ALT, alanine aminotransferase; AST, aspartate aminotransferase; INR, International normalization ratio (for blood clotting); GGT, gammaglutamyl transferase; Glu, glucose; Ins, insulin; HbA1c, glycosylated hemoglobin; HOMA-IR, Homeostasis Model for assessment of insulin resistance; Plt, platelet count; TG, triglycerides; AFP, alpha fetoprotein;
  2. AFP is considered elevated if greater than 400 ug/mL according to international guidelines